Media headlines about Arbutus Biopharma (NASDAQ:ABUS) have been trending somewhat positive this week, Accern reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Arbutus Biopharma earned a coverage optimism score of 0.08 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.5624266501264 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Arbutus Biopharma (ABUS) Downgraded by Zacks Investment Research (americanbankingnews.com)
- Roivant and Arbutus launch Genevant to develop new RNA drugs (bioworld.com)
- BRIEF-Arbutus And Roivant Launch Genevant Sciences With Platform To Develop Broad Range Of RNA Therapeutics … (reuters.com)
- Arbutus Biopharma Corporation (ABUS) Trading at $5.20 after Move Up (thecasualsmart.com)
- Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA … (globenewswire.com)
A number of analysts have commented on the company. ValuEngine raised Arbutus Biopharma from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research raised Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Thursday, March 22nd. BidaskClub lowered Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday, March 20th. Chardan Capital initiated coverage on Arbutus Biopharma in a report on Monday, March 19th. They set a “buy” rating and a $8.25 price objective for the company. Finally, Wedbush lowered Arbutus Biopharma from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $9.00 to $6.00 in a report on Monday, March 19th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $12.38.
Arbutus Biopharma (NASDAQ:ABUS) last released its earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.51). The business had revenue of $2.50 million during the quarter, compared to the consensus estimate of $0.70 million. Arbutus Biopharma had a negative net margin of 796.23% and a negative return on equity of 55.28%. research analysts expect that Arbutus Biopharma will post -1.7 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This story was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://stocknewstimes.com/2018/04/20/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-arbutus-biopharma-abus-share-price.html.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.